<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Bisphosphonate therapy for the treatment of osteoporosis</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Bisphosphonate therapy for the treatment of osteoporosis</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Bisphosphonate therapy for the treatment of osteoporosis</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Author:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Harold N Rosen, MD</a></dd><dt><span> </span>Section Editors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Clifford J Rosen, MD</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Kenneth E Schmader, MD</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Katya Rubinow, MD</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> May 03, 2023.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H1"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>Osteoporosis is caused by the cumulative effect of bone resorption in excess of bone formation. Bisphosphonates inhibit bone resorption with relatively few side effects. As a result, they are widely used to prevent osteoporotic fractures.</p><p>The use of bisphosphonates for the management of osteoporosis will be reviewed here. An overview of other treatment options for osteoporosis is discussed separately. (See  <a class="medical medical_review" href="/d/html/2064.html" rel="external">"Overview of the management of low bone mass and osteoporosis in postmenopausal women"</a> and  <a class="medical medical_review" href="/d/html/2059.html" rel="external">"Treatment of osteoporosis in men"</a> and  <a class="medical medical_review" href="/d/html/2060.html" rel="external">"Evaluation and treatment of premenopausal osteoporosis"</a>.)</p><p>Bisphosphonates are also used in the management of hypercalcemia, Paget disease, and a number of malignancies, including multiple myeloma, breast cancer, and prostate cancer. These topics are all reviewed separately in the appropriate topic reviews.</p><p class="headingAnchor" id="H1067803"><span class="h1">GENERAL PRINCIPLES</span></p><p class="headingAnchor" id="H397398767"><span class="h2">Lifestyle measures</span><span class="headingEndMark"> — </span>Lifestyle measures include adequate calcium and vitamin D, exercise, smoking cessation, counseling on fall prevention, and avoidance of heavy alcohol use. These measures should be adopted universally to reduce bone loss in people with osteoporosis. (See  <a class="medical medical_review" href="/d/html/2064.html" rel="external">"Overview of the management of low bone mass and osteoporosis in postmenopausal women", section on 'Lifestyle measures to reduce bone loss'</a> and  <a class="medical medical_review" href="/d/html/2059.html" rel="external">"Treatment of osteoporosis in men", section on 'Lifestyle measures'</a>.)</p><p class="headingAnchor" id="H731518304"><span class="h2">Pharmacologic therapy</span><span class="headingEndMark"> — </span>In addition to lifestyle measures, patients at high risk for fracture should receive pharmacologic therapy. Recommendations in whom to initiate pharmacologic therapy are reviewed elsewhere. (See  <a class="medical medical_review" href="/d/html/2064.html" rel="external">"Overview of the management of low bone mass and osteoporosis in postmenopausal women", section on 'Patient selection'</a> and  <a class="medical medical_review" href="/d/html/2059.html" rel="external">"Treatment of osteoporosis in men", section on 'Patient selection'</a>.)</p><p>In the absence of specific contraindications, oral bisphosphonates are considered initial pharmacologic therapy for most patients at high risk for fracture. We prefer oral bisphosphonates as initial therapy because of their efficacy, favorable cost, and the availability of long-term safety data. (See  <a class="medical medical_review" href="/d/html/2064.html" rel="external">"Overview of the management of low bone mass and osteoporosis in postmenopausal women", section on 'Patient selection'</a> and  <a class="medical medical_review" href="/d/html/2059.html" rel="external">"Treatment of osteoporosis in men", section on 'Initial therapy: Bisphosphonates'</a> and <a class="local">'Choice of bisphosphonate'</a> below.)</p><p class="headingAnchor" id="H3422893804"><span class="h2">Contraindications to bisphosphonates</span><span class="headingEndMark"> — </span>Oral bisphosphonates should not be used in the following settings:</p><p class="bulletIndent1"><span class="glyph">●</span>As initial therapy in patients with esophageal disorders (eg, achalasia, esophageal stricture, esophageal varices, Barrett's esophagus) or with an inability to follow the dosing requirements (eg, stay upright for at least 30 minutes).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>After certain types of bariatric surgery in which surgical anastomoses are present in the gastrointestinal (GI) tract (eg, Roux-en-Y gastric bypass).</p><p></p><p>For patients with contraindications to oral bisphosphonates, GI intolerance to oral bisphosphonates, or an inability to follow the dosing requirements (eg, stay upright for at least 30 minutes), we suggest an intravenous (IV) bisphosphonate formulation. (IV bisphosphonates are acceptable after bariatric procedures as long as vitamin D has been assessed and is in the normal range.) (See <a class="local">'Choice of bisphosphonate'</a> below and  <a class="medical medical_review" href="/d/html/2064.html" rel="external">"Overview of the management of low bone mass and osteoporosis in postmenopausal women", section on 'Gastrointestinal malabsorption or difficulty with dosing requirements'</a>.)</p><p>Oral and IV bisphosphonates should not be used routinely in patients with chronic kidney disease (CKD) and an estimated glomerular filtration rate (eGFR) &lt;30 to 35 mL/min/1.73 m<sup>2</sup>. (See <a class="local">'Use in chronic kidney disease'</a> below.)</p><p>Additional therapies for patients with contraindications to bisphosphonates are reviewed elsewhere. (See  <a class="medical medical_review" href="/d/html/2059.html" rel="external">"Treatment of osteoporosis in men", section on 'Contraindications/intolerance to any bisphosphonates'</a> and  <a class="medical medical_review" href="/d/html/2064.html" rel="external">"Overview of the management of low bone mass and osteoporosis in postmenopausal women", section on 'Contraindications or intolerance to any bisphosphonates'</a>.)</p><p class="headingAnchor" id="H1068060"><span class="h1">CHOICE OF BISPHOSPHONATE</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Oral</strong> – We suggest <a class="drug drug_general" data-topicid="9427" href="/d/drug information/9427.html" rel="external">alendronate</a> as the initial choice of oral bisphosphonate  (<a class="graphic graphic_table graphicRef131712" data-inline-graphics="131712" href="/d/graphic/131712.html" rel="external">table 1</a>), in part due to direct evidence showing residual fracture benefit in selected patients after completing a five-year course of therapy [<a href="#rid1">1</a>]. <a class="drug drug_general" data-topicid="10242" href="/d/drug information/10242.html" rel="external">Risedronate</a> is a reasonable alternative.</p><p></p><p class="bulletIndent1">Generic <a class="drug drug_general" data-topicid="9427" href="/d/drug information/9427.html" rel="external">alendronate</a> and <a class="drug drug_general" data-topicid="10242" href="/d/drug information/10242.html" rel="external">risedronate</a> are available in many countries, including the United States. Most patients prefer the convenience of the once-weekly regimen.</p><p></p><p class="bulletIndent1">For people with well-controlled gastroesophageal reflux or peptic ulcer disease, initial therapy with either <a class="drug drug_general" data-topicid="10242" href="/d/drug information/10242.html" rel="external">risedronate</a> or <a class="drug drug_general" data-topicid="9427" href="/d/drug information/9427.html" rel="external">alendronate</a> is also acceptable.</p><p></p><p class="bulletIndent1">For people with a history of gastrointestinal (GI) side effects to <a class="drug drug_general" data-topicid="9427" href="/d/drug information/9427.html" rel="external">alendronate</a> (but without esophageal disorders), <a class="drug drug_general" data-topicid="10242" href="/d/drug information/10242.html" rel="external">risedronate</a> can be substituted as some patients may have fewer GI side effects.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Intravenous</strong> <strong>(IV)</strong> – For patients with contraindications or intolerance to oral bisphosphonates, we suggest IV <a class="drug drug_general" data-topicid="9902" href="/d/drug information/9902.html" rel="external">zoledronic acid</a> because it has been shown to prevent fractures in clinical trials  (<a class="graphic graphic_table graphicRef131712" href="/d/graphic/131712.html" rel="external">table 1</a>). Generic zoledronic acid is available in the United States, United Kingdom, and other countries.</p><p></p><p><a class="drug drug_general" data-topicid="9427" href="/d/drug information/9427.html" rel="external">Alendronate</a>, <a class="drug drug_general" data-topicid="10242" href="/d/drug information/10242.html" rel="external">risedronate</a>, <a class="drug drug_general" data-topicid="8887" href="/d/drug information/8887.html" rel="external">ibandronate</a>, and <a class="drug drug_general" data-topicid="9902" href="/d/drug information/9902.html" rel="external">zoledronic acid</a> have all been shown to improve bone mineral density (BMD) in postmenopausal women and in men with osteoporosis [<a href="#rid2">2,3</a>]. In addition, a systematic review of trials published between 2005 and 2019 confirmed the vertebral fracture prevention efficacy of several bisphosphonates, including alendronate, risedronate, zoledronic acid, and ibandronate, compared with placebo [<a href="#rid4">4,5</a>]. Alendronate, risedronate, and zoledronic acid also reduce the risk of hip and other nonvertebral fractures [<a href="#rid4">4-6</a>]. Bisphosphonates also reduce vertebral fracture in men. (See  <a class="medical medical_review" href="/d/html/2059.html" rel="external">"Treatment of osteoporosis in men", section on 'Initial therapy: Bisphosphonates'</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Alendronate</strong> – <a class="drug drug_general" data-topicid="9427" href="/d/drug information/9427.html" rel="external">Alendronate</a> increases BMD  (<a class="graphic graphic_figure graphicRef63767" href="/d/graphic/63767.html" rel="external">figure 1</a>) and decreases the risk of vertebral fractures in women with and without a prior history of vertebral fracture [<a href="#rid7">7-10</a>]. In a meta-analysis of 11 trials of alendronate therapy in postmenopausal women, there were fewer vertebral fractures with alendronate for both primary prevention (1.4 versus 3.4 percent, RR 0.55, 95% CI 0.38-0.80) and secondary prevention (6.2 versus 12.2 percent, relative risk [RR] 0.55, 95% CI 0.43-0.69) [<a href="#rid11">11</a>]. In addition, alendronate reduced nonvertebral fractures (7.3 versus 9.3 percent, RR 0.77, 95% CI 0.64-0.92) and hip fractures (0.3 versus 1.3 percent, RR 0.47, 95% CI 0.26-0.85) in patients with a previous fracture (secondary prevention) [<a href="#rid11">11</a>]. Alendronate has been shown to be effective in Black American women [<a href="#rid12">12</a>] and in older women in long-term care facilities [<a href="#rid13">13,14</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Risedronate</strong> – <a class="drug drug_general" data-topicid="10242" href="/d/drug information/10242.html" rel="external">Risedronate</a> improves BMD and reduces fracture risk in postmenopausal osteoporosis [<a href="#rid15">15-21</a>]. In a meta-analysis of eight randomized trials of risedronate versus placebo in postmenopausal women with established osteoporosis, risedronate reduced the risk of vertebral (RR 0.64, 95% CI 0.54-0.77) and nonvertebral (RR 0.73, 95% CI 0.61-0.87) fracture [<a href="#rid16">16</a>].</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>In one of the larger trials in the meta-analysis, the three-year rates of new vertebral fractures with <a class="drug drug_general" data-topicid="10242" href="/d/drug information/10242.html" rel="external">risedronate</a> versus placebo were 11.3 and 16.3 percent (RR 0.59, 95% CI 0.42-0.82), and 5.2 versus 8.4 percent for nonvertebral fractures (RR 0.61, 95% CI 0.39-0.94) [<a href="#rid15">15</a>].</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>In the largest trial evaluating hip fracture efficacy, <a class="drug drug_general" data-topicid="10242" href="/d/drug information/10242.html" rel="external">risedronate</a> significantly reduced the risk of hip fracture among older women with confirmed osteoporosis (1.9 versus 3.2 percent with placebo [RR 0.6, 95% CI 0.4-0.9]) but not among older women (&gt;80 years) selected primarily on the basis of nonskeletal risk factors, such as poor gait, smoking, and propensity to fall (4.2 versus 5.1 percent [RR 0.8, 95% CI 0.6-1.2]) [<a href="#rid21">21</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Alendronate</strong><strong> versus </strong><strong>risedronate</strong> – <a class="drug drug_general" data-topicid="9427" href="/d/drug information/9427.html" rel="external">Alendronate</a> and <a class="drug drug_general" data-topicid="10242" href="/d/drug information/10242.html" rel="external">risedronate</a> have been compared in one randomized trial and in some retrospective observational trials. In the randomized trial, alendronate increased bone density more than risedronate at all sites after 12 months [<a href="#rid22">22</a>]. Results persisted in year 2 of the study [<a href="#rid23">23</a>]. However, there were no differences in the incidence of fractures, which were reported only as adverse events. In one observational study, treatment with risedronate was associated with a decreased risk of fracture in the first year of therapy compared with alendronate [<a href="#rid24">24</a>]. However, this study was limited by the inability to accurately characterize fracture risk at baseline between the two groups. A prospective randomized trial with fracture as a defined endpoint is necessary to determine if there is a difference in fracture prevention efficacy between the two bisphosphonates, and it is very unlikely such a trial will ever be conducted.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Zoledronic acid</strong> – <a class="drug drug_general" data-topicid="9902" href="/d/drug information/9902.html" rel="external">Zoledronic acid</a> is a bisphosphonate that is administered as a 15-minute intravenous infusion once yearly. It increases BMD and reduces fracture risk [<a href="#rid25">25-29</a>]. In the Health Outcomes and Reduced Incidence with Zoledronic Acid Once Yearly (HORIZON) studies, yearly IV zoledronic acid (for three consecutive years) compared with placebo [<a href="#rid25">25,26</a>]:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Improved BMD.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Decreased vertebral (3.3 versus 10.9 percent [RR 0.30, 95% CI 0.24-0.38]) and hip (1.4 versus 2.5 percent [HR 0.59, 95% CI 0.42-0.83]) fractures in postmenopausal women with BMD T-score ≤-2.5 or with T-score ≤-1.5 and radiologic evidence of vertebral fracture(s).</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Decreased any new clinical fracture in men and women with recent hip fracture (8.6 and 13.9 percent [HR 0.65, 95% CI 0.50-0.84]).</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Decreased all-cause mortality, a secondary safety endpoint, in men and women with recent hip fracture (9.6 versus 13.3 percent [HR 0.72, 95% CI 0.56-0.93]).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Ibandronate</strong><strong> </strong>– <a class="drug drug_general" data-topicid="8887" href="/d/drug information/8887.html" rel="external">Ibandronate</a> increases BMD and reduces the risk of vertebral fracture; a significant reduction in hip fracture has not been demonstrated [<a href="#rid30">30-35</a>]. Meta-analyses of phase III studies, in which fracture data were collected as adverse effects, have shown a reduction in nonvertebral fractures with higher doses of ibandronate (pooled data from IV dosing [2 or 3 mg every 2 to 3 months] and oral dosing [150 mg monthly]) [<a href="#rid34">34,35</a>]. However, there are no direct nonvertebral fracture efficacy data for IV ibandronate.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Therapies/regimens not recommended</strong> – A number of other bisphosphonates are available, but they are no longer used for osteoporosis.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><a class="drug drug_general" data-topicid="8426" href="/d/drug information/8426.html" rel="external">Etidronate</a> was the first bisphosphonate used in the treatment of osteoporosis. It increased BMD and decreased vertebral, but not nonvertebral, fractures, and it was never approved for treating postmenopausal osteoporosis. In addition, there was concern that long-term use may cause osteomalacia. Therefore, it has been superseded by other bisphosphonates.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Tiludronate, an effective therapy for Paget disease of bone, has not been demonstrated to be effective for the treatment or prevention of osteoporosis. (See  <a class="medical medical_review" href="/d/html/5596.html" rel="external">"Treatment of Paget disease of bone"</a>.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><a class="drug drug_general" data-topicid="9736" href="/d/drug information/9736.html" rel="external">Pamidronate</a>, an IV preparation, has been used primarily for the treatment of hypercalcemia and prevention of skeletal complications in multiple myeloma, breast cancer, and prostate cancer. (See  <a class="medical medical_review" href="/d/html/850.html" rel="external">"Treatment of hypercalcemia"</a>.)</p><p></p><p class="bulletIndent2"><a class="drug drug_general" data-topicid="9736" href="/d/drug information/9736.html" rel="external">Pamidronate</a> is also effective for osteoporosis and has been used for patients with osteoporosis who could not tolerate oral bisphosphonates [<a href="#rid36">36</a>]. However, it has been superseded by <a class="drug drug_general" data-topicid="9902" href="/d/drug information/9902.html" rel="external">zoledronic acid</a> (and in some cases IV <a class="drug drug_general" data-topicid="8887" href="/d/drug information/8887.html" rel="external">ibandronate</a>) because these drugs have fracture efficacy data.</p><p></p><p class="bulletIndent1">We also suggest not using bisphosphonates in combination with other osteoporosis drugs, as the additional BMD benefits are small, and there is no proven additional fracture benefit [<a href="#rid37">37-42</a>]. Furthermore, there is theoretical concern that combination antiresorptive therapy could over suppress bone turnover and cause increased skeletal fragility. (See  <a class="medical medical_review" href="/d/html/104424.html" rel="external">"Risks of bisphosphonate therapy in patients with osteoporosis", section on 'Atypical femur fracture'</a>.)</p><p></p><p class="bulletIndent1">Because <a class="drug drug_general" data-topicid="10178" href="/d/drug information/10178.html" rel="external">teriparatide</a> (parathyroid hormone [PTH]) stimulates bone formation and bisphosphonates reduce bone resorption, it has been hypothesized that combining the two therapies would increase bone density more than either therapy alone. However, the addition of a bisphosphonate to teriparatide therapy provides little additional benefit for BMD, and in some studies, the addition of bisphosphonates actually reduced the increase in BMD from teriparatide. It is important to note that fracture data are unavailable for combination therapy. (See  <a class="medical medical_review" href="/d/html/2059.html" rel="external">"Treatment of osteoporosis in men", section on 'Combination therapy'</a> and  <a class="medical medical_review" href="/d/html/2057.html" rel="external">"Parathyroid hormone/parathyroid hormone-related protein analog therapy for osteoporosis", section on 'Combination therapy not recommended'</a>.)</p><p></p><p class="headingAnchor" id="H2"><span class="h1">PRACTICAL MANAGEMENT ISSUES</span></p><p class="headingAnchor" id="H4561856"><span class="h2">Pretreatment evaluation</span><span class="headingEndMark"> — </span>Before starting bisphosphonates, the diagnosis should be confirmed  (<a class="graphic graphic_algorithm graphicRef142794" data-inline-graphics="142794" href="/d/graphic/142794.html" rel="external">algorithm 1</a>). Patients should be evaluated to detect potentially remediable causes of or other contributing factors to osteoporosis.</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Biochemical assessment</strong> – This evaluation includes assessment for hypocalcemia, vitamin D deficiency, and renal impairment by measuring serum  (<a class="graphic graphic_algorithm graphicRef131952" href="/d/graphic/131952.html" rel="external">algorithm 2</a>):</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Calcium</p><p class="bulletIndent2"><span class="glyph">•</span>25-hydroxyvitamin D (25[OH]D)</p><p class="bulletIndent2"><span class="glyph">•</span>Creatinine</p><p></p><p class="bulletIndent1">For both oral and intravenous (IV) bisphosphonates, correction of hypocalcemia and/or vitamin D deficiency (to at least 20 ng/mL [50 nmol/L]) is necessary prior to administration. (See  <a class="medical medical_review" href="/d/html/2023.html" rel="external">"Calcium and vitamin D supplementation in osteoporosis"</a> and  <a class="medical medical_review" href="/d/html/2022.html" rel="external">"Vitamin D deficiency in adults: Definition, clinical manifestations, and treatment"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Assess comorbidities</strong> – In addition, assessment for comorbidities that may preclude use or alter the administration of bisphosphonates is necessary. For oral bisphosphonates, this typically includes a careful history to detect any abnormalities of the esophagus (stricture, achalasia) and an inability to remain upright for at least 30 to 60 minutes.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Plans for invasive dental procedures</strong> – For both oral and IV bisphosphonates, we also inquire about imminent plans for invasive dental procedures (extractions, implants) and discuss risk factors for developing osteonecrosis of the jaw (ONJ), a rare complication of IV or oral therapy. (See  <a class="medical medical_review" href="/d/html/104424.html" rel="external">"Risks of bisphosphonate therapy in patients with osteoporosis", section on 'Osteonecrosis of the jaw'</a>.)</p><p></p><p class="bulletIndent1">If a dental implant or extraction is already planned, we frequently delay bisphosphonate therapy for a few months until healing of the jaw is complete. If a patient is already taking bisphosphonates, the approach is uncertain and there are few data to guide management. Some clinicians ask patients to discontinue bisphosphonates and resume again when healing is complete, while others suggest not stopping bisphosphonates. Guidelines from the American Association of Oral and Maxillofacial Surgeons suggest performing dentoalveolar surgery, such as extractions and implants, as usual in patients who have been treated with oral bisphosphonates for less than four years and have no clinical risk factors [<a href="#rid43">43</a>]. They suggest discontinuing bisphosphonates if a patient has been treated for more than four years or has taken concomitant glucocorticoids. This topic is reviewed in more detail separately. (See  <a class="medical medical_review" href="/d/html/104424.html" rel="external">"Risks of bisphosphonate therapy in patients with osteoporosis", section on 'Osteonecrosis of the jaw'</a>.)</p><p></p><p class="headingAnchor" id="H3"><span class="h2">Oral regimen</span><span class="headingEndMark"> — </span>Bisphosphonates are poorly absorbed orally (less than 1 percent of the dose) [<a href="#rid44">44</a>] and must be taken on an empty stomach for maximal absorption. The following regimen is recommended to maximize absorption and minimize the risk of esophageal adverse effects. (See  <a class="medical medical_review" href="/d/html/104424.html" rel="external">"Risks of bisphosphonate therapy in patients with osteoporosis", section on 'Gastrointestinal'</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>Bisphosphonates should not be given to patients with active upper gastrointestinal (GI) disease.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Bisphosphonates should be discontinued in patients who develop any symptoms of esophagitis.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Bisphosphonates should be taken alone on an empty stomach first thing in the morning with at least 240 mL (8 oz) of water. After administration, the patient should not have food, drink, medications, or supplements for at least one half-hour (<a class="drug drug_general" data-topicid="9427" href="/d/drug information/9427.html" rel="external">alendronate</a>, <a class="drug drug_general" data-topicid="10242" href="/d/drug information/10242.html" rel="external">risedronate</a>) or one hour (<a class="drug drug_general" data-topicid="8887" href="/d/drug information/8887.html" rel="external">ibandronate</a>).</p><p></p><p class="bulletIndent1">The reason for taking 8 oz of water is to minimize the risk of the tablet getting stuck in the esophagus. The reason for taking the medication while fasting and waiting one half-hour until eating or drinking is that bioavailability may be seriously impaired by ingestion with liquids other than plain water, such as mineral water, coffee, or juice; by retained gastric contents, as with insufficient fasting time or gastroparesis; or by eating or drinking too soon afterwards.</p><p></p><p class="bulletIndent1">The regimen for enteric-coated, delayed-release <a class="drug drug_general" data-topicid="10242" href="/d/drug information/10242.html" rel="external">risedronate</a> is different from that of other bisphosphonates. The enteric-coated, delayed-release formulation is taken immediately after breakfast with 4 oz of water [<a href="#rid45">45</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Patients should remain upright (sitting or standing) for at least 30 minutes after administration to minimize the risk of reflux.</p><p></p><p>Compliance is also important for optimal fracture reduction [<a href="#rid46">46-48</a>].</p><p class="headingAnchor" id="H4"><span class="h3">Timing of dose</span><span class="headingEndMark"> — </span>Administration of bisphosphonates first thing in the morning, prior to breakfast, appears to be important for bioavailability and subsequent suppression of bone turnover. This was illustrated in a randomized trial of nursing home residents who were assigned to <a class="drug drug_general" data-topicid="10242" href="/d/drug information/10242.html" rel="external">risedronate</a> or placebo between meals (after a two-hour fast) for 12 weeks, rather than before breakfast or the first liquid of the day [<a href="#rid49">49</a>]. Markers of bone turnover were not suppressed as they typically would be with before-breakfast administration, suggesting that this alternative schedule may not provide the desired effects on bone mineral density (BMD).</p><p class="headingAnchor" id="H5"><span class="h3">Calcium/vitamin D</span><span class="headingEndMark"> — </span>Vitamin D insufficiency and inadequate calcium intake are common in patients with osteoporosis. In the majority of bisphosphonate trials described below, calcium and vitamin D supplements were also administered. Therefore, patients receiving bisphosphonates should take supplemental calcium and vitamin D. However, calcium and other mineral (eg, magnesium, iron) supplements can interfere with the absorption of bisphosphonates, and they should not be taken for at least one hour after taking oral bisphosphonates. (See  <a class="medical medical_review" href="/d/html/2064.html" rel="external">"Overview of the management of low bone mass and osteoporosis in postmenopausal women", section on 'Calcium/vitamin D'</a> and  <a class="medical medical_review" href="/d/html/2023.html" rel="external">"Calcium and vitamin D supplementation in osteoporosis", section on 'Summary and recommendations'</a>.)</p><p class="headingAnchor" id="H6"><span class="h2">IV regimen</span><span class="headingEndMark"> — </span>Intravenous (IV) bisphosphonates (<a class="drug drug_general" data-topicid="9902" href="/d/drug information/9902.html" rel="external">zoledronic acid</a> and <a class="drug drug_general" data-topicid="8887" href="/d/drug information/8887.html" rel="external">ibandronate</a>) provide an alternative option for patients who cannot tolerate oral bisphosphonates or who have difficulty with dosing requirements, including an inability to sit upright for 30 to 60 minutes and/or to swallow a pill. Zoledronic acid (5 mg) is administered yearly and must be infused over a period of at least 15 minutes, whereas ibandronate is administered every 3 months as a 15- to 30-second IV injection.</p><p>Prior to receiving IV bisphosphonates, patients should be assessed for hypocalcemia, vitamin D deficiency, and renal impairment by measuring serum calcium, creatinine, and 25(OH)D, as described above. (See <a class="local">'Pretreatment evaluation'</a> above.)</p><p>Hypocalcemia may occur in patients treated with IV bisphosphonates (see  <a class="medical medical_review" href="/d/html/104424.html" rel="external">"Risks of bisphosphonate therapy in patients with osteoporosis", section on 'Hypocalcemia'</a>). It is more likely to occur in those individuals with vitamin D deficiency and, therefore, can be minimized by vitamin D and calcium supplementation. Individuals with vitamin D deficiency (25[OH]D &lt;20 ng/mL [50 nmol/L]) should be treated prior to the infusion, until the serum 25(OH)D level is above 20 ng/mL. (See  <a class="medical medical_review" href="/d/html/2022.html" rel="external">"Vitamin D deficiency in adults: Definition, clinical manifestations, and treatment"</a>.)</p><p>There have been isolated reports of renal impairment and acute renal failure after <a class="drug drug_general" data-topicid="9902" href="/d/drug information/9902.html" rel="external">zoledronic acid</a> administration, particularly in patients with multiple myeloma but also rarely in those treated for osteoporosis and those receiving concurrent diuretic therapy [<a href="#rid50">50-52</a>]. This occurrence may be related to infusion of zoledronic acid too rapidly. Prior to each zoledronic acid infusion, clinicians should measure serum creatinine and make sure that patients are adequately hydrated. Zoledronic acid should be infused over a period of at least 15 minutes. In patients taking other nephrotoxic drugs or diuretics, periodic postinfusion measurement of serum creatinine should be considered. Zoledronic acid is not recommended for use in patients with creatinine clearance ≤35 mL/min [<a href="#rid50">50</a>]. (See  <a class="medical medical_review" href="/d/html/104424.html" rel="external">"Risks of bisphosphonate therapy in patients with osteoporosis", section on 'Impaired kidney function'</a>.)</p><p>IV bisphosphonates may be associated with flu-like symptoms, which can be minimized by longer infusion times (eg, 45 to 60 minutes) and can be treated with <a class="drug drug_general" data-topicid="9242" href="/d/drug information/9242.html" rel="external">acetaminophen</a> or <a class="drug drug_general" data-topicid="8547" href="/d/drug information/8547.html" rel="external">ibuprofen</a> [<a href="#rid53">53</a>]. IV bisphosphonates may also cause hypocalcemia, which can be minimized by delaying infusion until vitamin D deficiency has been corrected. (See  <a class="medical medical_review" href="/d/html/104424.html" rel="external">"Risks of bisphosphonate therapy in patients with osteoporosis", section on 'Flu-like symptoms'</a>.)</p><p class="headingAnchor" id="H1068613"><span class="h1">MONITORING RESPONSE TO THERAPY</span><span class="headingEndMark"> — </span>Serial bone mineral density (BMD) measurements are performed to assess the clinical response to therapy. (See  <a class="medical medical_review" href="/d/html/2064.html" rel="external">"Overview of the management of low bone mass and osteoporosis in postmenopausal women", section on 'Monitoring response to initial pharmacotherapy'</a>.)</p><p>BMD that is stable or improving is evidence for a treatment response. (See <a class="local">'Duration of therapy'</a> below.)</p><p>The finding of a clinically significant BMD decrease in a treated patient should trigger additional evaluation for contributing factors, which may include poor adherence to therapy, inadequate gastrointestinal (GI) absorption, inadequate intake of calcium and vitamin D, or the development of a disease or disorder with adverse skeletal effects. Calcium and vitamin D supplementation should be verified, and some evaluation for secondary causes of bone loss should be performed. (See  <a class="medical medical_review" href="/d/html/2056.html" rel="external">"Overview of dual-energy x-ray absorptiometry", section on 'Interpretation of BMD changes'</a> and  <a class="medical medical_review" href="/d/html/2035.html" rel="external">"Clinical manifestations, diagnosis, and evaluation of osteoporosis in postmenopausal women", section on 'Evaluation'</a>.)</p><p>When to switch and which therapy to select for patients who fail initial therapy are reviewed separately. (See  <a class="medical medical_review" href="/d/html/2064.html" rel="external">"Overview of the management of low bone mass and osteoporosis in postmenopausal women", section on 'BMD decreased or fracture during therapy'</a>.)</p><p class="headingAnchor" id="H1068767"><span class="h1">DURATION OF THERAPY</span></p><p class="headingAnchor" id="H4002798"><span class="h2">Our approach</span></p><p class="headingAnchor" id="H1658271372"><span class="h3">Risk stratified management</span><span class="headingEndMark"> — </span>For patients taking <a class="drug drug_general" data-topicid="9427" href="/d/drug information/9427.html" rel="external">alendronate</a> or <a class="drug drug_general" data-topicid="10242" href="/d/drug information/10242.html" rel="external">risedronate</a> for five years or who received <a class="drug drug_general" data-topicid="9902" href="/d/drug information/9902.html" rel="external">zoledronic acid</a> once yearly for three years, our approach is based upon the clinical risk for subsequent fracture. The potential benefits of continued fracture reduction, however, must be considered in light of the potential risks of long-term therapy. Duration of therapy should be individualized based upon patient characteristics and preferences. This approach is largely consistent with that of a Task Force of the American Society of Bone and Mineral Research [<a href="#rid54">54</a>].</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Low risk for fracture</strong> – For patients at low risk for fracture in the near future (eg, stable bone mineral density [BMD], no previous vertebral or hip fractures), we suggest discontinuing the drug (after three years for <a class="drug drug_general" data-topicid="9902" href="/d/drug information/9902.html" rel="external">zoledronic acid</a>, five years for <a class="drug drug_general" data-topicid="9427" href="/d/drug information/9427.html" rel="external">alendronate</a> or <a class="drug drug_general" data-topicid="10242" href="/d/drug information/10242.html" rel="external">risedronate</a>), as there appears to be residual BMD and fracture benefit. (See <a class="local">'Alendronate'</a> below and <a class="local">'Risedronate'</a> below and <a class="local">'Zoledronic acid'</a> below and <a class="local">'Length of holiday'</a> below.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>High risk for fracture</strong> – For patients at highest risk for fracture (history of osteoporotic fracture before or during therapy, T-score below -3.0 in the absence of fractures) who are taking <a class="drug drug_general" data-topicid="9427" href="/d/drug information/9427.html" rel="external">alendronate</a> or <a class="drug drug_general" data-topicid="10242" href="/d/drug information/10242.html" rel="external">risedronate</a>, we suggest continuing therapy for up to 10 years as clinical trial data show maintenance of BMD and fracture benefits with no increased risk of adverse events [<a href="#rid55">55</a>]. For similar women treated with <a class="drug drug_general" data-topicid="9902" href="/d/drug information/9902.html" rel="external">zoledronic acid</a>, we would continue therapy up to six years. Alendronate, risedronate, and zoledronic acid have demonstrated efficacy for 10, 7, and 6 years, respectively [<a href="#rid55">55-58</a>].</p><p></p><p>There are few data to guide decisions about duration of therapy [<a href="#rid58">58-60</a>]. A systematic review showed that after three to five years of bisphosphonate therapy, bisphosphonate continuation compared with discontinuation reduced the risk of radiographic (<a class="drug drug_general" data-topicid="9902" href="/d/drug information/9902.html" rel="external">zoledronic acid</a>) and clinical (<a class="drug drug_general" data-topicid="9427" href="/d/drug information/9427.html" rel="external">alendronate</a>) vertebral fracture, but it did not reduce nonvertebral fracture [<a href="#rid58">58</a>].</p><p>The US Food and Drug Administration (FDA) performed an analysis of the three major bisphosphonate extension studies [<a href="#rid61">61,62</a>]. In two of these trials (described in detail below), postmenopausal women who had taken bisphosphonates for three to five years were randomly assigned to continue bisphosphonates or switch to placebo, and they were followed for three to five years [<a href="#rid1">1,57,63</a>].</p><p class="bulletIndent1"><span class="glyph">●</span>Femoral neck BMD was maintained in patients who continued to take bisphosphonates. In patients randomly assigned to placebo, femoral neck BMD decreased during the first one to two years of placebo and then stabilized and remained higher than baseline. Bone density of the spine continued to increase in groups taking bisphosphonates and placebo.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Fracture rates (vertebral and nonvertebral combined) in patients who received bisphosphonate treatment for six or more years were similar to those in patients who switched to placebo (9.3 to 10.6 versus 8.0 to 8.8 percent) [<a href="#rid61">61</a>]. The fracture assessment was limited by the small sample size in the extension trials, differences in study design of the individual trials, and post hoc nature of the analysis.</p><p></p><p>Additional data examining the risk of fracture after discontinuation of bisphosphonate therapy are needed to better define the duration of therapy for individual patients and for the specific bisphosphonate [<a href="#rid59">59</a>].</p><p class="headingAnchor" id="H4002751"><span class="h3">Alendronate</span><span class="headingEndMark"> — </span>For some women, stopping <a class="drug drug_general" data-topicid="9427" href="/d/drug information/9427.html" rel="external">alendronate</a> after five years is reasonable as there appears to be a residual benefit on BMD and fractures for up to five years. This was illustrated in the Fracture Intervention Trial Long-term Extension (FLEX) with 1099 postmenopausal women who had previously received alendronate for five years in the Fracture Intervention Trial (FIT) [<a href="#rid1">1</a>].</p><p>At the completion of FIT, women were randomly assigned to an additional five years of <a class="drug drug_general" data-topicid="9427" href="/d/drug information/9427.html" rel="external">alendronate</a> (5 or 10 mg daily) or placebo. Women at highest risk for fracture were excluded from FLEX (those with FLEX baseline T-scores either below -3.5, or below their FIT baseline).</p><p>In women who were switched to placebo after five years of <a class="drug drug_general" data-topicid="9427" href="/d/drug information/9427.html" rel="external">alendronate</a>, the following results were seen [<a href="#rid1">1</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>A gradual decline in BMD (-2.4 and -3.7 percent at the total hip and spine, respectively), but mean BMD remained at or higher than levels 10 years earlier.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>A gradual rise in biochemical markers of bone turnover. However, the values were still lower than 10 years previously.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>No significant difference between placebo and <a class="drug drug_general" data-topicid="9427" href="/d/drug information/9427.html" rel="external">alendronate</a> groups in the rate of nonvertebral (18.9 and 19.0 percent) or morphometric vertebral fractures detected by lateral spine radiographs (11.3 and 9.8 percent [relative risk (RR) 0.86, 95% CI 0.60-1.22]). However, there was a higher risk of vertebral fractures clinically detected by participants' clinicians and spine radiograph (5.3 and 2.4 percent for placebo and alendronate, respectively [RR 0.45, 95% CI 0.24-0.85]).</p><p></p><p>The two groups did not differ in adverse events. No one developed osteonecrosis of the jaw (ONJ). Bone biopsy showed no qualitative abnormalities in either group.</p><p>In a post hoc analysis of women without vertebral fracture at FLEX baseline, continuation of <a class="drug drug_general" data-topicid="9427" href="/d/drug information/9427.html" rel="external">alendronate</a> compared with placebo reduced the number of participants with nonvertebral fracture in the subgroup of women with FLEX baseline femoral neck T-scores of -2.5 or less (16 versus 21 participants) but not with T-scores better than -2.5 (45 versus 27 participants) [<a href="#rid64">64</a>]. This study was limited by the small numbers of nonvertebral fractures within the subgroups and the post hoc nature of the analysis.</p><p>In summary, stopping <a class="drug drug_general" data-topicid="9427" href="/d/drug information/9427.html" rel="external">alendronate</a> after five years of therapy results in a gradual decline in BMD and increase in biochemical markers of bone turnover but no significantly higher risk of fracture (except for clinical vertebral fracture) in most women. Thus, stopping bisphosphonate therapy after five years may be reasonable for some low-risk women (eg, no history of fracture and T-scores better than -2.5) as long as they are followed carefully by BMD and assessment of risk factors.</p><p>However, the FLEX trial does not address the impact of stopping therapy in women at highest risk for fracture (T-score below -3.5), as they were excluded from the trial. In these women, we suggest continuing <a class="drug drug_general" data-topicid="9427" href="/d/drug information/9427.html" rel="external">alendronate</a> for up to 10 years as BMD and fracture benefits were maintained with no increased risk of adverse events.</p><p class="headingAnchor" id="H1069087"><span class="h3">Risedronate</span><span class="headingEndMark"> — </span>In the absence of direct evidence, our suggestion for discontinuing <a class="drug drug_general" data-topicid="10242" href="/d/drug information/10242.html" rel="external">risedronate</a> is based upon indirect evidence from the <a class="drug drug_general" data-topicid="9427" href="/d/drug information/9427.html" rel="external">alendronate</a> extension trial (FLEX) [<a href="#rid1">1</a>]. We typically discontinue risedronate after five years of use in low-risk women (eg, no history of fracture and T-scores better than -2.5) as long as they are followed carefully by BMD and assessment of risk factors.</p><p>There are no randomized extension trial data comparing continuous treatment with <a class="drug drug_general" data-topicid="10242" href="/d/drug information/10242.html" rel="external">risedronate</a> versus switching to placebo. When risedronate is discontinued after three years, its beneficial effects on BMD and markers of bone turnover appear to revert partially or completely within one year, as reported in an extension of the Vertebral Efficacy with Risedronate Therapy (VERT) trial [<a href="#rid15">15,63</a>]. In this observational extension study, women who received risedronate or placebo for three years were reassessed one year after stopping therapy (but continuing vitamin D supplementation) [<a href="#rid63">63</a>]. BMD of the lumbar spine and femoral neck decreased (0.83 and 1.23 percent, respectively) in the group previously taking risedronate, although mean values remained higher than baseline (lumbar spine) and placebo (lumbar spine and femoral neck). However, markers of bone turnover returned to baseline and were the same as the placebo group within one year. Nonetheless, the incidence of new vertebral fractures in patients previously treated with risedronate remained lower (6.5 versus 11.6 percent).</p><p class="headingAnchor" id="H1069147"><span class="h3">Zoledronic acid</span><span class="headingEndMark"> — </span>The majority of patients who receive <a class="drug drug_general" data-topicid="9902" href="/d/drug information/9902.html" rel="external">zoledronic acid</a> once yearly for three years do not require subsequent infusions of zoledronic acid for at least the next three years. However, in patients at high risk for fractures (eg, existing vertebral fracture or femoral neck BMD T-score &lt;-2.5 after an initial course of therapy), continuing yearly zoledronic acid beyond three years may provide some benefit, but the potential benefits must be considered in light of the potential risks of long-term therapy. (See  <a class="medical medical_review" href="/d/html/104424.html" rel="external">"Risks of bisphosphonate therapy in patients with osteoporosis", section on 'Osteonecrosis of the jaw'</a>.)</p><p>The beneficial effects of a three-year course of <a class="drug drug_general" data-topicid="9902" href="/d/drug information/9902.html" rel="external">zoledronic acid</a> (5 mg yearly) appear to be maintained in the subsequent three years, as illustrated by the finding of an extension of the Health Outcomes and Reduced Incidence with Zoledronic Acid Once Yearly (HORIZON) Pivotal Fracture Trial [<a href="#rid25">25</a>], in which a subset of women (n = 1233 of 3889) who had received zoledronic acid (5 mg yearly) for three years in the core study were randomly assigned to three additional years of zoledronic acid or placebo [<a href="#rid57">57</a>]. The mean change in femoral neck BMD (the primary endpoint) from year 3 to 6 was +0.24 and -0.80 percent, respectively. The mean change in lumbar spine (a secondary endpoint) was +3.2 and +1.18, respectively. There were fewer morphometric vertebral fractures (a secondary endpoint) in the group that received zoledronic acid for six years (3 versus 6.2 percent; odds ratio [OR] 0.51, 95% CI 0.26-0.95). However, the overall fracture event rate was low, reducing the precision of the analysis. There was no difference in the incidence of nonvertebral, clinical vertebral, or all clinical fractures. Markers of bone turnover remained below pretreatment values in both groups. A greater proportion of patients in the active treatment group had transient increases in serum creatinine (&gt;0.5 mg/dL). There were no cases of atypical fractures, and there was one case of ONJ in the group receiving zoledronic acid for six years. (See  <a class="medical medical_review" href="/d/html/104424.html" rel="external">"Risks of bisphosphonate therapy in patients with osteoporosis", section on 'Osteonecrosis of the jaw'</a>.)</p><p class="headingAnchor" id="H1069225"><span class="h2">Length of holiday</span><span class="headingEndMark"> — </span>We typically restart bisphosphonates within the first five years of the drug holiday when any of the following occur:</p><p class="bulletIndent1"><span class="glyph">●</span>Reproducible bone loss (approximately 5 percent) on at least two dual-energy x-ray absorptiometry (DXA) measurements taken at least two years apart, using the same make and model DXA scanner.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Evidence of bone loss on one DXA measurement at the spine <strong>and</strong> the hip.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Evidence of bone loss on one DXA measurement at either site <strong>and</strong> accompanied by a fasting C-terminal telopeptide of type I collagen (CTX) &gt;600 pg/mL (ie, above the upper limit of the premenopausal reference range).</p><p></p><p>As an alternative, bisphosphonates can be restarted after a three- to five-year holiday in women who showed improvement during their initial course of bisphosphonates and did not have a previous fracture.</p><p>There are no data to support one strategy over another for determining when to restart bisphosphonates after a drug holiday. In clinical practice, the decision to resume the drug is often based on a combination of factors, including duration of the holiday, decrease in BMD, clinical risk factors for fracture, a new osteoporotic fracture, and increase in markers of bone turnover [<a href="#rid54">54,65-68</a>]. (See  <a class="medical medical_review" href="/d/html/2041.html" rel="external">"Use of biochemical markers of bone turnover in osteoporosis", section on 'Duration of therapy'</a>.)</p><p class="headingAnchor" id="H1070880"><span class="h1">ADVERSE EFFECTS</span><span class="headingEndMark"> — </span>The risks of bisphosphonates in patients treated for osteoporosis are reviewed in detail separately. (See  <a class="medical medical_review" href="/d/html/104424.html" rel="external">"Risks of bisphosphonate therapy in patients with osteoporosis"</a>.)</p><p class="headingAnchor" id="H1069765"><span class="h1">SPECIAL POPULATIONS</span></p><p class="headingAnchor" id="H1069771"><span class="h2">Use in chronic kidney disease</span><span class="headingEndMark"> — </span>Bisphosphonates are generally not recommended for those with creatinine clearance below 30 to 35 mL/min. Patients with chronic kidney disease (CKD) with creatinine clearance above 30 to 35 mL/min are usually managed similarly to patients with normal renal function [<a href="#rid69">69-71</a>]. However, there are few data about fracture prevention efficacy and long-term adverse effects in subjects with reduced renal function.</p><p>The evaluation of osteoporosis and unique management issues in patients with CKD are reviewed in detail separately. (See  <a class="medical medical_review" href="/d/html/13914.html" rel="external">"Osteoporosis in patients with chronic kidney disease: Diagnosis and evaluation"</a>.)</p><p class="headingAnchor" id="H1069834"><span class="h2">Use immediately after fracture</span><span class="headingEndMark"> — </span>A history of a fragility (low-trauma) fracture is an important risk factor for subsequent fracture. If a patient is not already treated, pharmacologic therapy (typically bisphosphonates) should be initiated in patients with fragility fracture to prevent subsequent fracture [<a href="#rid72">72</a>]. (See  <a class="medical medical_review" href="/d/html/2064.html" rel="external">"Overview of the management of low bone mass and osteoporosis in postmenopausal women", section on 'Patient selection'</a>.)</p><p>Bisphosphonates inhibit bone resorption by suppressing osteoclast activity. There is theoretical concern that bisphosphonates may impair fracture healing because fracture healing requires callus remodeling and the coupled activity of osteoclasts and osteoblasts. Thus, important questions are whether bisphosphonates can be initiated in the immediate postfracture period and whether there is delayed fracture healing in patients who fracture while on therapy. There are few data to guide these clinical decisions [<a href="#rid73">73-76</a>].</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Treatment-naïve patients</strong> – We typically initiate bisphosphonates two weeks postfracture, as long as the patient is able to sit upright for at least 30 minutes (oral bisphosphonates). This is also a time when patients are more mobile, taking less pain medication, and may therefore have fewer gastrointestinal (GI) symptoms that might otherwise be ascribed to oral bisphosphonates.</p><p></p><p class="bulletIndent1">In the Health Outcomes and Reduced Incidence with <a class="drug drug_general" data-topicid="9902" href="/d/drug information/9902.html" rel="external">Zoledronic Acid</a> Once Yearly (HORIZON) Recurrent Fracture Trial, older adults with hip fracture were randomly assigned to receive intravenous (IV) zoledronic acid or placebo within three months of surgical repair of the hip fracture [<a href="#rid26">26</a>]. In a preplanned secondary analysis of the data, the overall incidence of delayed healing in the zoledronic acid and placebo groups was similar (3.2 and 2.7 percent, respectively) [<a href="#rid77">77</a>]. In a post hoc analysis, there was also no difference in nonunion rates between zoledronic acid and placebo when zoledronic was administered early (within two weeks), between two and four weeks, four and six weeks, or six weeks after hip fracture repair [<a href="#rid77">77</a>].</p><p></p><p class="bulletIndent1">In another trial specifically designed to assess the effect of bisphosphonates on fracture healing, 50 women who had surgical repair of an osteoporotic distal radial fracture were randomly assigned to initiation of bisphosphonates two weeks or three months after the surgery [<a href="#rid78">78</a>]. There was no significant difference between the two groups in time to radiographic union (6.7 weeks). Similarly, initiation of <a class="drug drug_general" data-topicid="10242" href="/d/drug information/10242.html" rel="external">risedronate</a> one week, one month, or three months after internal fixation for repair of an intertrochanteric fracture did not have any effect on mean time to fracture healing, rate of nonunion at 24 weeks, or functional outcomes at one year [<a href="#rid79">79</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Patients already taking bisphosphonates</strong> – A separate question is whether patients already taking bisphosphonates at the time of fracture will have a delay in fracture healing.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Typical fragility fractures</strong> – In most postmenopausal women who have been taking bisphosphonates for &lt;5 years and who have a typical osteoporotic fragility fracture, we do not discontinue bisphosphonates because of concern about delayed fracture healing. However, if there is concern that the fracture occurred because the patient is not absorbing or responding to bisphosphonates, additional evaluation and consideration of alternative therapy is warranted. (See <a class="local">'Monitoring response to therapy'</a> above.)</p><p></p><p class="bulletIndent2">In a retrospective study, 196 patients treated for a distal radius fracture were evaluated [<a href="#rid80">80</a>]. Compared with patients not taking bisphosphonates (n = 153), those taking bisphosphonates at the time of the injury had a longer mean time to radiographic union (55 versus 49 days). Although statistically significant, this difference is unlikely clinically relevant.</p><p></p><p class="bulletIndent2">In a nested case-control study of 19,731 patients with fractures of the humerus, radiographic nonunion occurred in 81 (0.4 percent) [<a href="#rid81">81</a>]. There was no difference in pre-fracture bisphosphonate exposure in patients with nonunion and 810 matched controls without nonunion (3.7 and 3.5 percent, respectively).</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Atypical femur fractures</strong> – In patients with atypical femur fractures who have been taking bisphosphonates, we discontinue bisphosphonates as delayed healing has been reported in such patients [<a href="#rid82">82</a>]. There is theoretical concern that prolonged bisphosphonate therapy can lead to oversuppression of bone turnover ("frozen bone") and increased skeletal fragility, resulting in atypical fracture (particularly subtrochanteric or diaphyseal fractures). The absolute risk of an atypical fracture is low. (See  <a class="medical medical_review" href="/d/html/104424.html" rel="external">"Risks of bisphosphonate therapy in patients with osteoporosis", section on 'Atypical femur fracture'</a>.)</p><p></p><p class="headingAnchor" id="H787542317"><span class="h1">SOCIETY GUIDELINE LINKS</span><span class="headingEndMark"> — </span>Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See  <a class="medical medical_society_guidelines" href="/d/html/105492.html" rel="external">"Society guideline links: Osteoporosis"</a>.)</p><p class="headingAnchor" id="H9987211"><span class="h1">INFORMATION FOR PATIENTS</span><span class="headingEndMark"> — </span>UpToDate offers two types of patient education materials, "The Basics" and "Beyond the Basics." The Basics patient education pieces are written in plain language, at the 5<sup>th</sup> to 6<sup>th</sup> grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10<sup>th</sup> to 12<sup>th</sup> grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.</p><p>Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on "patient info" and the keyword(s) of interest.)</p><p class="bulletIndent1"><span class="glyph">●</span>Basics topics (see  <a class="medical medical_basics" href="/d/html/15482.html" rel="external">"Patient education: Osteoporosis (The Basics)"</a> and  <a class="medical medical_basics" href="/d/html/83978.html" rel="external">"Patient education: Medicines for osteoporosis (The Basics)"</a>)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Beyond the Basics topics (see  <a class="medical medical_patient" href="/d/html/2160.html" rel="external">"Patient education: Osteoporosis prevention and treatment (Beyond the Basics)"</a>)</p><p></p><p class="headingAnchor" id="H53"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Overview</strong> <strong>of bisphosphonates </strong>– Bisphosphonates, one of the available therapeutic options for the management of osteoporosis, inhibit bone resorption with relatively few side effects. As a result, they are widely used for the prevention of osteoporotic fractures  (<a class="graphic graphic_table graphicRef131712" href="/d/graphic/131712.html" rel="external">table 1</a>). (See  <a class="medical medical_review" href="/d/html/2064.html" rel="external">"Overview of the management of low bone mass and osteoporosis in postmenopausal women"</a> and  <a class="medical medical_review" href="/d/html/2059.html" rel="external">"Treatment of osteoporosis in men", section on 'Initial therapy: Bisphosphonates'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Initial treatment of osteoporosis</strong> – For the initial treatment of osteoporosis, we suggest oral bisphosphonates (<a class="grade" href="https://medilib.ir/uptodate/show/grade_5" rel="external">Grade 2B</a>). (See  <a class="medical medical_review" href="/d/html/2064.html" rel="external">"Overview of the management of low bone mass and osteoporosis in postmenopausal women", section on 'Choice of initial therapy'</a> and  <a class="medical medical_review" href="/d/html/2059.html" rel="external">"Treatment of osteoporosis in men", section on 'Choice of therapy'</a>.)</p><p></p><p class="bulletIndent1">We prefer oral bisphosphonates (over other osteoporosis drugs) as initial therapy because of their efficacy, favorable cost, and the availability of long-term safety data  (<a class="graphic graphic_algorithm graphicRef131952" href="/d/graphic/131952.html" rel="external">algorithm 2</a>). (See <a class="local">'Choice of bisphosphonate'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Choice of oral bisphosphonate</strong> – We suggest <a class="drug drug_general" data-topicid="9427" href="/d/drug information/9427.html" rel="external">alendronate</a> as the initial choice of bisphosphonate (<a class="grade" href="https://medilib.ir/uptodate/show/grade_6" rel="external">Grade 2C</a>). <a class="drug drug_general" data-topicid="10242" href="/d/drug information/10242.html" rel="external">Risedronate</a> is a reasonable alternative. Individuals with well-controlled gastroesophageal reflux or peptic ulcer disease can also take alendronate or risedronate.</p><p></p><p class="bulletIndent1">We most commonly use <a class="drug drug_general" data-topicid="9427" href="/d/drug information/9427.html" rel="external">alendronate</a>, in part due to direct evidence showing residual fracture benefit in selected patients after completing a five-year course of therapy. Generic alendronate and <a class="drug drug_general" data-topicid="10242" href="/d/drug information/10242.html" rel="external">risedronate</a> are available in many countries, including the United States. Most patients prefer the convenience of the once-weekly regimen. Although once-monthly oral <a class="drug drug_general" data-topicid="8887" href="/d/drug information/8887.html" rel="external">ibandronate</a> may be more convenient for patients, a reduction in hip fracture risk has not been established, and if the patient likes the once-monthly regimen, risedronate can be given that way. (See <a class="local">'Choice of bisphosphonate'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Contraindications to oral bisphosphonates</strong> – <a class="drug drug_general" data-topicid="9902" href="/d/drug information/9902.html" rel="external">Zoledronic acid</a> administered intravenously should be used instead of a bisphosphonate administered orally in patients who have esophageal disorders (achalasia, scleroderma involving the esophagus, esophageal strictures, varices), certain types of bariatric surgery in which surgical anastomoses are present in the gastrointestinal (GI) tract (eg, Roux-en-Y gastric bypass), GI intolerance to oral bisphosphonates, or an inability to follow the dosing requirements of oral bisphosphonates, including an inability to sit upright for 30 to 60 minutes and/or to swallow a pill  (<a class="graphic graphic_algorithm graphicRef131952" href="/d/graphic/131952.html" rel="external">algorithm 2</a>). Zoledronic acid is the only intravenous (IV) bisphosphonate that has demonstrated efficacy for fracture prevention and is, therefore, our agent of choice. (See <a class="local">'Contraindications to bisphosphonates'</a> above and <a class="local">'Choice of bisphosphonate'</a> above and  <a class="medical medical_review" href="/d/html/104424.html" rel="external">"Risks of bisphosphonate therapy in patients with osteoporosis", section on 'Gastrointestinal'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Pretreatment evaluation</strong> — Before starting bisphosphonates, the diagnosis should be confirmed  (<a class="graphic graphic_algorithm graphicRef142794" href="/d/graphic/142794.html" rel="external">algorithm 1</a>). Patients should be assessed for hypocalcemia, vitamin D deficiency, and renal impairment by measuring serum  (<a class="graphic graphic_algorithm graphicRef131952" href="/d/graphic/131952.html" rel="external">algorithm 2</a>):</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Calcium</p><p class="bulletIndent2"><span class="glyph">•</span>25-hydroxyvitamin D (25[OH]D)</p><p class="bulletIndent2"><span class="glyph">•</span>Creatinine</p><p></p><p class="bulletIndent1">For both oral and IV bisphosphonates, correction of hypocalcemia and/or vitamin D deficiency (to ≥20 ng/mL [50 nmol/L]) is necessary prior to administration. All patients should maintain adequate ongoing calcium and vitamin D intake. (See  <a class="medical medical_review" href="/d/html/2023.html" rel="external">"Calcium and vitamin D supplementation in osteoporosis"</a> and  <a class="medical medical_review" href="/d/html/2022.html" rel="external">"Vitamin D deficiency in adults: Definition, clinical manifestations, and treatment"</a>.)</p><p></p><p class="bulletIndent1">Oral and IV bisphosphonates should not be used routinely in patients with chronic kidney disease (CKD) and an estimated glomerular filtration rate (eGFR) &lt;30 to 35 mL/min/1.73 m<sup>2</sup>. (See <a class="local">'Use in chronic kidney disease'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Monitoring</strong> – Serial bone mineral density (BMD) measurements are performed to assess the clinical response to therapy. The finding of a clinically significant BMD decrease in a treated patient should trigger additional evaluation for contributing factors, which may include poor adherence to therapy, inadequate GI absorption, inadequate intake of calcium and vitamin D, or the development of a disease or disorder with adverse skeletal effects. (See <a class="local">'Monitoring response to therapy'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Duration of therapy</strong> – For patients taking <a class="drug drug_general" data-topicid="9427" href="/d/drug information/9427.html" rel="external">alendronate</a> or <a class="drug drug_general" data-topicid="10242" href="/d/drug information/10242.html" rel="external">risedronate</a> for five years or who received <a class="drug drug_general" data-topicid="9902" href="/d/drug information/9902.html" rel="external">zoledronic acid</a> once yearly for three years, who have a stable BMD, no previous vertebral fractures, and who are at low risk for fracture in the near future, we suggest discontinuing the drug (<a class="grade" href="https://medilib.ir/uptodate/show/grade_6" rel="external">Grade 2C</a>). (See <a class="local">'Our approach'</a> above.)</p><p></p><p class="bulletIndent1">However, for women at highest risk for fracture (history of osteoporotic fracture before or during therapy, T-score below -3.0 in the absence of fractures) who are taking <a class="drug drug_general" data-topicid="9427" href="/d/drug information/9427.html" rel="external">alendronate</a> or <a class="drug drug_general" data-topicid="10242" href="/d/drug information/10242.html" rel="external">risedronate</a>, we continue therapy for up to 10 years as clinical trial data show maintenance of BMD and fracture benefits with no increased risk of adverse events. For similar women treated with <a class="drug drug_general" data-topicid="9902" href="/d/drug information/9902.html" rel="external">zoledronic acid</a>, we would continue therapy up to six years.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>After discontinuation</strong> – For patients in whom bisphosphonates have been discontinued, we monitor BMD. We typically restart bisphosphonates when there is persistent bone loss (approximately 5 percent) at the femoral neck on at least two dual-energy x-ray absorptiometry (DXA) measurements taken at least two years apart, using the same make and model DXA scanner. (See <a class="local">'Length of holiday'</a> above.)</p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Black DM, Schwartz AV, Ensrud KE, et al. Effects of continuing or stopping alendronate after 5 years of treatment: the Fracture Intervention Trial Long-term Extension (FLEX): a randomized trial. JAMA 2006; 296:2927.</a></li><li><a class="nounderline abstract_t">Yates J. A meta-analysis characterizing the dose-response relationships for three oral nitrogen-containing bisphosphonates in postmenopausal women. Osteoporos Int 2013; 24:253.</a></li><li><a class="nounderline abstract_t">Zhang J, Wang R, Zhao YL, et al. Efficacy of intravenous zoledronic acid in the prevention and treatment of osteoporosis: a meta-analysis. Asian Pac J Trop Med 2012; 5:743.</a></li><li><a class="nounderline abstract_t">Crandall CJ, Newberry SJ, Diamant A, et al. Comparative effectiveness of pharmacologic treatments to prevent fractures: an updated systematic review. Ann Intern Med 2014; 161:711.</a></li><li><a class="nounderline abstract_t">Barrionuevo P, Kapoor E, Asi N, et al. Efficacy of Pharmacological Therapies for the Prevention of Fractures in Postmenopausal Women: A Network Meta-Analysis. J Clin Endocrinol Metab 2019; 104:1623.</a></li><li><a class="nounderline abstract_t">Freemantle N, Cooper C, Diez-Perez A, et al. Results of indirect and mixed treatment comparison of fracture efficacy for osteoporosis treatments: a meta-analysis. Osteoporos Int 2013; 24:209.</a></li><li><a class="nounderline abstract_t">Liberman UA, Weiss SR, Bröll J, et al. Effect of oral alendronate on bone mineral density and the incidence of fractures in postmenopausal osteoporosis. The Alendronate Phase III Osteoporosis Treatment Study Group. N Engl J Med 1995; 333:1437.</a></li><li><a class="nounderline abstract_t">Black DM, Cummings SR, Karpf DB, et al. Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Fracture Intervention Trial Research Group. Lancet 1996; 348:1535.</a></li><li><a class="nounderline abstract_t">Cummings SR, Black DM, Thompson DE, et al. Effect of alendronate on risk of fracture in women with low bone density but without vertebral fractures: results from the Fracture Intervention Trial. JAMA 1998; 280:2077.</a></li><li><a class="nounderline abstract_t">Rizzoli R, Greenspan SL, Bone G 3rd, et al. Two-year results of once-weekly administration of alendronate 70 mg for the treatment of postmenopausal osteoporosis. J Bone Miner Res 2002; 17:1988.</a></li><li><a class="nounderline abstract_t">Wells GA, Cranney A, Peterson J, et al. Alendronate for the primary and secondary prevention of osteoporotic fractures in postmenopausal women. Cochrane Database Syst Rev 2008; :CD001155.</a></li><li><a class="nounderline abstract_t">Bell NH, Bilezikian JP, Bone HG 3rd, et al. Alendronate increases bone mass and reduces bone markers in postmenopausal African-American women. J Clin Endocrinol Metab 2002; 87:2792.</a></li><li><a class="nounderline abstract_t">Ensrud KE, Black DM, Palermo L, et al. Treatment with alendronate prevents fractures in women at highest risk: results from the Fracture Intervention Trial. Arch Intern Med 1997; 157:2617.</a></li><li><a class="nounderline abstract_t">Greenspan SL, Schneider DL, McClung MR, et al. Alendronate improves bone mineral density in elderly women with osteoporosis residing in long-term care facilities. A randomized, double-blind, placebo-controlled trial. Ann Intern Med 2002; 136:742.</a></li><li><a class="nounderline abstract_t">Harris ST, Watts NB, Genant HK, et al. Effects of risedronate treatment on vertebral and nonvertebral fractures in women with postmenopausal osteoporosis: a randomized controlled trial. Vertebral Efficacy With Risedronate Therapy (VERT) Study Group. JAMA 1999; 282:1344.</a></li><li><a class="nounderline abstract_t">Cranney A, Tugwell P, Adachi J, et al. Meta-analyses of therapies for postmenopausal osteoporosis. III. Meta-analysis of risedronate for the treatment of postmenopausal osteoporosis. Endocr Rev 2002; 23:517.</a></li><li><a class="nounderline abstract_t">Heaney RP, Zizic TM, Fogelman I, et al. Risedronate reduces the risk of first vertebral fracture in osteoporotic women. Osteoporos Int 2002; 13:501.</a></li><li><a class="nounderline abstract_t">Reginster J, Minne HW, Sorensen OH, et al. Randomized trial of the effects of risedronate on vertebral fractures in women with established postmenopausal osteoporosis. Vertebral Efficacy with Risedronate Therapy (VERT) Study Group. Osteoporos Int 2000; 11:83.</a></li><li><a class="nounderline abstract_t">Brown JP, Kendler DL, McClung MR, et al. The efficacy and tolerability of risedronate once a week for the treatment of postmenopausal osteoporosis. Calcif Tissue Int 2002; 71:103.</a></li><li><a class="nounderline abstract_t">Delmas PD, McClung MR, Zanchetta JR, et al. Efficacy and safety of risedronate 150 mg once a month in the treatment of postmenopausal osteoporosis. Bone 2008; 42:36.</a></li><li><a class="nounderline abstract_t">McClung MR, Geusens P, Miller PD, et al. Effect of risedronate on the risk of hip fracture in elderly women. Hip Intervention Program Study Group. N Engl J Med 2001; 344:333.</a></li><li><a class="nounderline abstract_t">Rosen CJ, Hochberg MC, Bonnick SL, et al. Treatment with once-weekly alendronate 70 mg compared with once-weekly risedronate 35 mg in women with postmenopausal osteoporosis: a randomized double-blind study. J Bone Miner Res 2005; 20:141.</a></li><li><a class="nounderline abstract_t">Bonnick S, Saag KG, Kiel DP, et al. Comparison of weekly treatment of postmenopausal osteoporosis with alendronate versus risedronate over two years. J Clin Endocrinol Metab 2006; 91:2631.</a></li><li><a class="nounderline abstract_t">Silverman SL, Watts NB, Delmas PD, et al. Effectiveness of bisphosphonates on nonvertebral and hip fractures in the first year of therapy: the risedronate and alendronate (REAL) cohort study. Osteoporos Int 2007; 18:25.</a></li><li><a class="nounderline abstract_t">Black DM, Delmas PD, Eastell R, et al. Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis. N Engl J Med 2007; 356:1809.</a></li><li><a class="nounderline abstract_t">Lyles KW, Colón-Emeric CS, Magaziner JS, et al. Zoledronic acid and clinical fractures and mortality after hip fracture. N Engl J Med 2007; 357:1799.</a></li><li><a class="nounderline abstract_t">Reid IR, Brown JP, Burckhardt P, et al. Intravenous zoledronic acid in postmenopausal women with low bone mineral density. N Engl J Med 2002; 346:653.</a></li><li><a class="nounderline abstract_t">Grey A, Bolland MJ, Wattie D, et al. The antiresorptive effects of a single dose of zoledronate persist for two years: a randomized, placebo-controlled trial in osteopenic postmenopausal women. J Clin Endocrinol Metab 2009; 94:538.</a></li><li><a class="nounderline abstract_t">Reid IR, Horne AM, Mihov B, et al. Fracture Prevention with Zoledronate in Older Women with Osteopenia. N Engl J Med 2018; 379:2407.</a></li><li><a class="nounderline abstract_t">Chesnut CH 3rd, Skag A, Christiansen C, et al. Effects of oral ibandronate administered daily or intermittently on fracture risk in postmenopausal osteoporosis. J Bone Miner Res 2004; 19:1241.</a></li><li><a class="nounderline abstract_t">Reginster JY, Adami S, Lakatos P, et al. Efficacy and tolerability of once-monthly oral ibandronate in postmenopausal osteoporosis: 2 year results from the MOBILE study. Ann Rheum Dis 2006; 65:654.</a></li><li><a class="nounderline abstract_t">Delmas PD, Adami S, Strugala C, et al. Intravenous ibandronate injections in postmenopausal women with osteoporosis: one-year results from the dosing intravenous administration study. Arthritis Rheum 2006; 54:1838.</a></li><li><a class="nounderline abstract_t">Eisman JA, Civitelli R, Adami S, et al. Efficacy and tolerability of intravenous ibandronate injections in postmenopausal osteoporosis: 2-year results from the DIVA study. J Rheumatol 2008; 35:488.</a></li><li><a class="nounderline abstract_t">Harris ST, Blumentals WA, Miller PD. Ibandronate and the risk of non-vertebral and clinical fractures in women with postmenopausal osteoporosis: results of a meta-analysis of phase III studies. Curr Med Res Opin 2008; 24:237.</a></li><li><a class="nounderline abstract_t">Cranney A, Wells GA, Yetisir E, et al. Ibandronate for the prevention of nonvertebral fractures: a pooled analysis of individual patient data. Osteoporos Int 2009; 20:291.</a></li><li><a class="nounderline abstract_t">Miller RG, Chretien KC, Meoni LA, et al. Comparison of intravenous pamidronate to standard therapy for osteoporosis: use in patients unable to take oral bisphosphonates. J Clin Rheumatol 2005; 11:2.</a></li><li><a class="nounderline abstract_t">Wimalawansa SJ. A four-year randomized controlled trial of hormone replacement and bisphosphonate, alone or in combination, in women with postmenopausal osteoporosis. Am J Med 1998; 104:219.</a></li><li><a class="nounderline abstract_t">Bone HG, Greenspan SL, McKeever C, et al. Alendronate and estrogen effects in postmenopausal women with low bone mineral density. Alendronate/Estrogen Study Group. J Clin Endocrinol Metab 2000; 85:720.</a></li><li><a class="nounderline abstract_t">Lindsay R, Cosman F, Lobo RA, et al. Addition of alendronate to ongoing hormone replacement therapy in the treatment of osteoporosis: a randomized, controlled clinical trial. J Clin Endocrinol Metab 1999; 84:3076.</a></li><li><a class="nounderline abstract_t">Harris ST, Eriksen EF, Davidson M, et al. Effect of combined risedronate and hormone replacement therapies on bone mineral density in postmenopausal women. J Clin Endocrinol Metab 2001; 86:1890.</a></li><li><a class="nounderline abstract_t">Greenspan SL, Emkey RD, Bone HG, et al. Significant differential effects of alendronate, estrogen, or combination therapy on the rate of bone loss after discontinuation of treatment of postmenopausal osteoporosis. A randomized, double-blind, placebo-controlled trial. Ann Intern Med 2002; 137:875.</a></li><li><a class="nounderline abstract_t">Johnell O, Scheele WH, Lu Y, et al. Additive effects of raloxifene and alendronate on bone density and biochemical markers of bone remodeling in postmenopausal women with osteoporosis. J Clin Endocrinol Metab 2002; 87:985.</a></li><li class="breakAll">American Association of Oral and Maxillofacial Surgeons.Position paper: Medication-related osteonecrosis of the jaw - 2014 update http://www.aaoms.org/docs/position_papers/mronj_position_paper.pdf?pdf=MRONJ-Position-Paper (Accessed on October 01, 2014).</li><li><a class="nounderline abstract_t">Gertz BJ, Holland SD, Kline WF, et al. Studies of the oral bioavailability of alendronate. Clin Pharmacol Ther 1995; 58:288.</a></li><li><a class="nounderline abstract_t">McClung MR, Balske A, Burgio DE, et al. Treatment of postmenopausal osteoporosis with delayed-release risedronate 35 mg weekly for 2 years. Osteoporos Int 2013; 24:301.</a></li><li><a class="nounderline abstract_t">Siris ES, Harris ST, Rosen CJ, et al. Adherence to bisphosphonate therapy and fracture rates in osteoporotic women: relationship to vertebral and nonvertebral fractures from 2 US claims databases. Mayo Clin Proc 2006; 81:1013.</a></li><li><a class="nounderline abstract_t">Brookhart MA, Avorn J, Katz JN, et al. Gaps in treatment among users of osteoporosis medications: the dynamics of noncompliance. Am J Med 2007; 120:251.</a></li><li><a class="nounderline abstract_t">Patrick AR, Brookhart MA, Losina E, et al. The complex relation between bisphosphonate adherence and fracture reduction. J Clin Endocrinol Metab 2010; 95:3251.</a></li><li><a class="nounderline abstract_t">Agrawal S, Krueger DC, Engelke JA, et al. Between-meal risedronate does not alter bone turnover in nursing home residents. J Am Geriatr Soc 2006; 54:790.</a></li><li class="breakAll">US Food and Drug Administration. FDA Drug Safety Newsletter, Postmarket Reviews - Volume 2, Number 2, 2009 http://www.fda.gov/Drugs/DrugSafety/DrugSafetyNewsletter/ucm167883.htm (Accessed on October 08, 2009).</li><li><a class="nounderline abstract_t">Kuehn BM. Zoledronic acid risks. JAMA 2009; 302:838.</a></li><li><a class="nounderline abstract_t">Markowitz GS, Fine PL, Stack JI, et al. Toxic acute tubular necrosis following treatment with zoledronate (Zometa). Kidney Int 2003; 64:281.</a></li><li><a class="nounderline abstract_t">Wark JD, Bensen W, Recknor C, et al. Treatment with acetaminophen/paracetamol or ibuprofen alleviates post-dose symptoms related to intravenous infusion with zoledronic acid 5 mg. Osteoporos Int 2012; 23:503.</a></li><li><a class="nounderline abstract_t">Adler RA, El-Hajj Fuleihan G, Bauer DC, et al. Managing Osteoporosis in Patients on Long-Term Bisphosphonate Treatment: Report of a Task Force of the American Society for Bone and Mineral Research. J Bone Miner Res 2016; 31:16.</a></li><li><a class="nounderline abstract_t">Bone HG, Hosking D, Devogelaer JP, et al. Ten years' experience with alendronate for osteoporosis in postmenopausal women. N Engl J Med 2004; 350:1189.</a></li><li><a class="nounderline abstract_t">Mellström DD, Sörensen OH, Goemaere S, et al. Seven years of treatment with risedronate in women with postmenopausal osteoporosis. Calcif Tissue Int 2004; 75:462.</a></li><li><a class="nounderline abstract_t">Black DM, Reid IR, Boonen S, et al. The effect of 3 versus 6 years of zoledronic acid treatment of osteoporosis: a randomized extension to the HORIZON-Pivotal Fracture Trial (PFT). J Bone Miner Res 2012; 27:243.</a></li><li><a class="nounderline abstract_t">Fink HA, MacDonald R, Forte ML, et al. Long-Term Drug Therapy and Drug Discontinuations and Holidays for Osteoporosis Fracture Prevention: A Systematic Review. Ann Intern Med 2019; 171:37.</a></li><li><a class="nounderline abstract_t">Siu A, Allore H, Brown D, et al. National Institutes of Health Pathways to Prevention Workshop: Research Gaps for Long-Term Drug Therapies for Osteoporotic Fracture Prevention. Ann Intern Med 2019; 171:51.</a></li><li><a class="nounderline abstract_t">Izano MA, Lo JC, Adams AL, et al. Bisphosphonate Treatment Beyond 5 Years and Hip Fracture Risk in Older Women. JAMA Netw Open 2020; 3:e2025190.</a></li><li class="breakAll">http://www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/DrugSafetyandRiskManagementAdvisoryCommittee/UCM270958.pdf (Accessed on June 13, 2012).</li><li><a class="nounderline abstract_t">Whitaker M, Guo J, Kehoe T, Benson G. Bisphosphonates for osteoporosis--where do we go from here? N Engl J Med 2012; 366:2048.</a></li><li><a class="nounderline abstract_t">Watts NB, Chines A, Olszynski WP, et al. Fracture risk remains reduced one year after discontinuation of risedronate. Osteoporos Int 2008; 19:365.</a></li><li><a class="nounderline abstract_t">Schwartz AV, Bauer DC, Cummings SR, et al. Efficacy of continued alendronate for fractures in women with and without prevalent vertebral fracture: the FLEX trial. J Bone Miner Res 2010; 25:976.</a></li><li><a class="nounderline abstract_t">Watts NB, Diab DL. Long-term use of bisphosphonates in osteoporosis. J Clin Endocrinol Metab 2010; 95:1555.</a></li><li><a class="nounderline abstract_t">Lewiecki EM, Bilezikian JP, Khosla S, et al. Osteoporosis update from the 2010 santa fe bone symposium. J Clin Densitom 2011; 14:1.</a></li><li><a class="nounderline abstract_t">McClung M, Harris ST, Miller PD, et al. Bisphosphonate therapy for osteoporosis: benefits, risks, and drug holiday. Am J Med 2013; 126:13.</a></li><li><a class="nounderline abstract_t">Adler RA. Duration of anti-resorptive therapy for osteoporosis. Endocrine 2016; 51:222.</a></li><li><a class="nounderline abstract_t">Miller PD. Treatment of osteoporosis in chronic kidney disease and end-stage renal disease. Curr Osteoporos Rep 2005; 3:5.</a></li><li><a class="nounderline abstract_t">Linnebur SA, Milchak JL. Assessment of oral bisphosphonate use in elderly patients with varying degrees of kidney function. Am J Geriatr Pharmacother 2004; 2:213.</a></li><li><a class="nounderline abstract_t">Miller PD, Roux C, Boonen S, et al. Safety and efficacy of risedronate in patients with age-related reduced renal function as estimated by the Cockcroft and Gault method: a pooled analysis of nine clinical trials. J Bone Miner Res 2005; 20:2105.</a></li><li><a class="nounderline abstract_t">Conley RB, Adib G, Adler RA, et al. Secondary Fracture Prevention: Consensus Clinical Recommendations from a Multistakeholder Coalition. J Bone Miner Res 2020; 35:36.</a></li><li><a class="nounderline abstract_t">Ng AJ, Yue B, Joseph S, Richardson M. Delayed/non-union of upper limb fractures with bisphosphonates: systematic review and recommendations. ANZ J Surg 2014; 84:218.</a></li><li><a class="nounderline abstract_t">Molvik H, Khan W. Bisphosphonates and their influence on fracture healing: a systematic review. Osteoporos Int 2015; 26:1251.</a></li><li><a class="nounderline abstract_t">Larsson S, Fazzalari NL. Anti-osteoporosis therapy and fracture healing. Arch Orthop Trauma Surg 2014; 134:291.</a></li><li><a class="nounderline abstract_t">Goldhahn J, Féron JM, Kanis J, et al. Implications for fracture healing of current and new osteoporosis treatments: an ESCEO consensus paper. Calcif Tissue Int 2012; 90:343.</a></li><li><a class="nounderline abstract_t">Colón-Emeric C, Nordsletten L, Olson S, et al. Association between timing of zoledronic acid infusion and hip fracture healing. Osteoporos Int 2011; 22:2329.</a></li><li><a class="nounderline abstract_t">Gong HS, Song CH, Lee YH, et al. Early initiation of bisphosphonate does not affect healing and outcomes of volar plate fixation of osteoporotic distal radial fractures. J Bone Joint Surg Am 2012; 94:1729.</a></li><li><a class="nounderline abstract_t">Kim TY, Ha YC, Kang BJ, et al. Does early administration of bisphosphonate affect fracture healing in patients with intertrochanteric fractures? J Bone Joint Surg Br 2012; 94:956.</a></li><li><a class="nounderline abstract_t">Rozental TD, Vazquez MA, Chacko AT, et al. Comparison of radiographic fracture healing in the distal radius for patients on and off bisphosphonate therapy. J Hand Surg Am 2009; 34:595.</a></li><li><a class="nounderline abstract_t">Solomon DH, Hochberg MC, Mogun H, Schneeweiss S. The relation between bisphosphonate use and non-union of fractures of the humerus in older adults. Osteoporos Int 2009; 20:895.</a></li><li><a class="nounderline abstract_t">Edwards BJ, Bunta AD, Lane J, et al. Bisphosphonates and nonhealing femoral fractures: analysis of the FDA Adverse Event Reporting System (FAERS) and international safety efforts: a systematic review from the Research on Adverse Drug Events And Reports (RADAR) project. J Bone Joint Surg Am 2013; 95:297.</a></li></ol></div><div id="topicVersionRevision">Topic 2030 Version 51.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17190893" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : Effects of continuing or stopping alendronate after 5 years of treatment: the Fracture Intervention Trial Long-term Extension (FLEX): a randomized trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23100120" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : A meta-analysis characterizing the dose-response relationships for three oral nitrogen-containing bisphosphonates in postmenopausal women.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22805729" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Efficacy of intravenous zoledronic acid in the prevention and treatment of osteoporosis: a meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25199883" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Comparative effectiveness of pharmacologic treatments to prevent fractures: an updated systematic review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30907957" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Efficacy of Pharmacological Therapies for the Prevention of Fractures in Postmenopausal Women: A Network Meta-Analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22832638" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Results of indirect and mixed treatment comparison of fracture efficacy for osteoporosis treatments: a meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7477143" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Effect of oral alendronate on bone mineral density and the incidence of fractures in postmenopausal osteoporosis. The Alendronate Phase III Osteoporosis Treatment Study Group.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8950879" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Fracture Intervention Trial Research Group.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9875874" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Effect of alendronate on risk of fracture in women with low bone density but without vertebral fractures: results from the Fracture Intervention Trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12412806" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Two-year results of once-weekly administration of alendronate 70 mg for the treatment of postmenopausal osteoporosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18253985" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Alendronate for the primary and secondary prevention of osteoporotic fractures in postmenopausal women.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12050252" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Alendronate increases bone mass and reduces bone markers in postmenopausal African-American women.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9531231" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Treatment with alendronate prevents fractures in women at highest risk: results from the Fracture Intervention Trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12020142" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Alendronate improves bone mineral density in elderly women with osteoporosis residing in long-term care facilities. A randomized, double-blind, placebo-controlled trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10527181" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Effects of risedronate treatment on vertebral and nonvertebral fractures in women with postmenopausal osteoporosis: a randomized controlled trial. Vertebral Efficacy With Risedronate Therapy (VERT) Study Group.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12202466" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Meta-analyses of therapies for postmenopausal osteoporosis. III. Meta-analysis of risedronate for the treatment of postmenopausal osteoporosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12107665" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Risedronate reduces the risk of first vertebral fracture in osteoporotic women.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10663363" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Randomized trial of the effects of risedronate on vertebral fractures in women with established postmenopausal osteoporosis. Vertebral Efficacy with Risedronate Therapy (VERT) Study Group.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12085156" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : The efficacy and tolerability of risedronate once a week for the treatment of postmenopausal osteoporosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17920005" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Efficacy and safety of risedronate 150 mg once a month in the treatment of postmenopausal osteoporosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11172164" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Effect of risedronate on the risk of hip fracture in elderly women. Hip Intervention Program Study Group.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15619680" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Treatment with once-weekly alendronate 70 mg compared with once-weekly risedronate 35 mg in women with postmenopausal osteoporosis: a randomized double-blind study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16636120" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Comparison of weekly treatment of postmenopausal osteoporosis with alendronate versus risedronate over two years.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17106785" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Effectiveness of bisphosphonates on nonvertebral and hip fractures in the first year of therapy: the risedronate and alendronate (REAL) cohort study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17476007" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17878149" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Zoledronic acid and clinical fractures and mortality after hip fracture.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11870242" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Intravenous zoledronic acid in postmenopausal women with low bone mineral density.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19050050" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : The antiresorptive effects of a single dose of zoledronate persist for two years: a randomized, placebo-controlled trial in osteopenic postmenopausal women.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30575489" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Fracture Prevention with Zoledronate in Older Women with Osteopenia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15231010" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : Effects of oral ibandronate administered daily or intermittently on fracture risk in postmenopausal osteoporosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16339289" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : Efficacy and tolerability of once-monthly oral ibandronate in postmenopausal osteoporosis: 2 year results from the MOBILE study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16729277" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : Intravenous ibandronate injections in postmenopausal women with osteoporosis: one-year results from the dosing intravenous administration study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18260172" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : Efficacy and tolerability of intravenous ibandronate injections in postmenopausal osteoporosis: 2-year results from the DIVA study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18047776" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : Ibandronate and the risk of non-vertebral and clinical fractures in women with postmenopausal osteoporosis: results of a meta-analysis of phase III studies.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18663402" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : Ibandronate for the prevention of nonvertebral fractures: a pooled analysis of individual patient data.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16357689" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : Comparison of intravenous pamidronate to standard therapy for osteoporosis: use in patients unable to take oral bisphosphonates.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9552083" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : A four-year randomized controlled trial of hormone replacement and bisphosphonate, alone or in combination, in women with postmenopausal osteoporosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10690882" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : Alendronate and estrogen effects in postmenopausal women with low bone mineral density. Alendronate/Estrogen Study Group.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10487668" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : Addition of alendronate to ongoing hormone replacement therapy in the treatment of osteoporosis: a randomized, controlled clinical trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11344179" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : Effect of combined risedronate and hormone replacement therapies on bone mineral density in postmenopausal women.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12458987" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : Significant differential effects of alendronate, estrogen, or combination therapy on the rate of bone loss after discontinuation of treatment of postmenopausal osteoporosis. A randomized, double-blind, placebo-controlled trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11889149" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : Additive effects of raloxifene and alendronate on bone density and biochemical markers of bone remodeling in postmenopausal women with osteoporosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11889149" id="rid42" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>43 : Additive effects of raloxifene and alendronate on bone density and biochemical markers of bone remodeling in postmenopausal women with osteoporosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7554702" id="rid43" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>44 : Studies of the oral bioavailability of alendronate.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23079690" id="rid44" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>45 : Treatment of postmenopausal osteoporosis with delayed-release risedronate 35 mg weekly for 2 years.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16901023" id="rid45" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>46 : Adherence to bisphosphonate therapy and fracture rates in osteoporotic women: relationship to vertebral and nonvertebral fractures from 2 US claims databases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17349448" id="rid46" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>47 : Gaps in treatment among users of osteoporosis medications: the dynamics of noncompliance.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20444916" id="rid47" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>48 : The complex relation between bisphosphonate adherence and fracture reduction.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16696745" id="rid48" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>49 : Between-meal risedronate does not alter bone turnover in nursing home residents.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16696745" id="rid49" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>50 : Between-meal risedronate does not alter bone turnover in nursing home residents.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid50" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>51 : Zoledronic acid risks</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12787420" id="rid51" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>52 : Toxic acute tubular necrosis following treatment with zoledronate (Zometa).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21331467" id="rid52" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>53 : Treatment with acetaminophen/paracetamol or ibuprofen alleviates post-dose symptoms related to intravenous infusion with zoledronic acid 5 mg.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26350171" id="rid53" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>54 : Managing Osteoporosis in Patients on Long-Term Bisphosphonate Treatment: Report of a Task Force of the American Society for Bone and Mineral Research.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15028823" id="rid54" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>55 : Ten years' experience with alendronate for osteoporosis in postmenopausal women.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15455188" id="rid55" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>56 : Seven years of treatment with risedronate in women with postmenopausal osteoporosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22161728" id="rid56" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>57 : The effect of 3 versus 6 years of zoledronic acid treatment of osteoporosis: a randomized extension to the HORIZON-Pivotal Fracture Trial (PFT).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31009947" id="rid57" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>58 : Long-Term Drug Therapy and Drug Discontinuations and Holidays for Osteoporosis Fracture Prevention: A Systematic Review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31009943" id="rid58" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>59 : National Institutes of Health Pathways to Prevention Workshop: Research Gaps for Long-Term Drug Therapies for Osteoporotic Fracture Prevention.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33284336" id="rid59" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>60 : Bisphosphonate Treatment Beyond 5 Years and Hip Fracture Risk in Older Women.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33284336" id="rid60" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>61 : Bisphosphonate Treatment Beyond 5 Years and Hip Fracture Risk in Older Women.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22571168" id="rid61" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>62 : Bisphosphonates for osteoporosis--where do we go from here?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17938986" id="rid62" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>63 : Fracture risk remains reduced one year after discontinuation of risedronate.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20200926" id="rid63" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>64 : Efficacy of continued alendronate for fractures in women with and without prevalent vertebral fracture: the FLEX trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20173017" id="rid64" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>65 : Long-term use of bisphosphonates in osteoporosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21295739" id="rid65" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>66 : Osteoporosis update from the 2010 santa fe bone symposium.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23177553" id="rid66" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>67 : Bisphosphonate therapy for osteoporosis: benefits, risks, and drug holiday.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26433739" id="rid67" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>68 : Duration of anti-resorptive therapy for osteoporosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16036095" id="rid68" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>69 : Treatment of osteoporosis in chronic kidney disease and end-stage renal disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15903279" id="rid69" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>70 : Assessment of oral bisphosphonate use in elderly patients with varying degrees of kidney function.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16294264" id="rid70" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>71 : Safety and efficacy of risedronate in patients with age-related reduced renal function as estimated by the Cockcroft and Gault method: a pooled analysis of nine clinical trials.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31538675" id="rid71" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>72 : Secondary Fracture Prevention: Consensus Clinical Recommendations from a Multistakeholder Coalition.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24529100" id="rid72" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>73 : Delayed/non-union of upper limb fractures with bisphosphonates: systematic review and recommendations.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25572046" id="rid73" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>74 : Bisphosphonates and their influence on fracture healing: a systematic review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22684739" id="rid74" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>75 : Anti-osteoporosis therapy and fracture healing.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22451221" id="rid75" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>76 : Implications for fracture healing of current and new osteoporosis treatments: an ESCEO consensus paper.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21153021" id="rid76" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>77 : Association between timing of zoledronic acid infusion and hip fracture healing.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22992762" id="rid77" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>78 : Early initiation of bisphosphonate does not affect healing and outcomes of volar plate fixation of osteoporotic distal radial fractures.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22733953" id="rid78" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>79 : Does early administration of bisphosphonate affect fracture healing in patients with intertrochanteric fractures?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19345861" id="rid79" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>80 : Comparison of radiographic fracture healing in the distal radius for patients on and off bisphosphonate therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18843515" id="rid80" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>81 : The relation between bisphosphonate use and non-union of fractures of the humerus in older adults.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23426763" id="rid81" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>82 : Bisphosphonates and nonhealing femoral fractures: analysis of the FDA Adverse Event Reporting System (FAERS) and international safety efforts: a systematic review from the Research on Adverse Drug Events And Reports (RADAR) project.</p>
</a>
</div>
</div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
